Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study

Japanese Journal of Clinical Oncology

Volumn 30, Issue 9, 2000, Pages 377-384

  Kurata, Takayasu ^a   Tamura, Tomohide ^a   Sasaki, Yasutsuna ^b   Fujii, Hirofumi ^b   Negoro, Shunichi ^c   Fukuoka, Masahiro ^d   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

JM216; Oral administration; Pharmacokinetics; Phase I study

Indexed keywords

DOXORUBICIN; SATRAPLATIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPHIL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; TUMOR;

EID: 0033658605     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd102     Document Type: Article

References (16)

1. Cumulative renal tubular damage associated with cisplatin nephrotoxicity
2. High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity
3. Ototoxicity of low- and moderate-dose cisplatin
4. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug
5. Preclinical toxicology and tissue platinum distribution of novel oral anti-tumor platinum complexes: Ammine/amine platinum (IV) dicarboxylates
6. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents
7. Lack of neurotoxicity of oral bisacetatoamminedichloro-cyclohexylamine-platinum [IV] in comparison to cisplatin and tetraplatin in the rat
8. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration
9. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) in vivo
10. Toxicity grading criteria of the Japan Clinical Oncology Group
11. Rapid determination of platinum by flameless atomic absorption spectrometry following the administration of cisplatin to cancer patients
12. Statistical moments in pharmacokinetics
13. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer
14. Phase I study of oral JM216 given twice daily
15. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
16. Biotransformation of the platinum drug JM216 following oral administration to cancer patients